Microparticles as autoadjuvants in the pathogenesis of SLE.
Nucleic acids represent the main source of autoantigens in systemic lupus erythematosus (SLE). DNA and RNA can exit the cell during cell death and, in the extracellular space, can be immunostimulatory. Also extracellularly, DNA and RNA can be incorporated into microparticles (MPs)-small, membrane-bound vesicles released from dying cells by blebbing. We suggest that MPs display autoantigens, such as RNA and DNA, in a highly immunostimulatory manner, enabling them to function as autoadjuvants. In the bone marrow, nucleic-acid-containing MP autoadjuvants might induce B-cell tolerance, whereas in the periphery, they might stimulate mature B cells that have escaped central tolerance. Indeed, because MP autoadjuvants can trigger several receptors, they could effectively provide apoptotic or activating signals to B cells. We would therefore advance the idea that a model for SLE based on MP autoadjuvants can provide a new paradigm to elucidate the mechanisms by which DNA and RNA affect the immune system and critically influence B-cell fate.
Pisetsky
David S
DS
Department of Medicine and Immunology, Duke University Medical Center, Medical Research Service, Durham VA Hospital, 151G Durham VAMC, 508 Fulton Street, Durham, NC 27705, USA. dpiset@acpub.duke.edu
Lipsky
Peter E
PE
D000276:Adjuvants, Immunologic; D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D055252:Cell-Derived Microparticles / Q000276:immunology*; D004247:DNA / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000209:etiology / Q000276:immunology*; D012313:RNA / Q000276:immunology*; D051193:Toll-Like Receptors / Q000276:immunology
D000276:Adjuvants, Immunologic; D000974:Antibodies, Antinuclear; D001324:Autoantigens; D051193:Toll-Like Receptors; D012313:RNA; D004247:DNA
Nature. 2007 Oct 4;449(7162):564-9
17873860
Clin Chem. 2001 Aug;47(8):1488-9
11468248
Blood Rev. 2007 May;21(3):157-71
17118501
J Immunol. 2009 Sep 1;183(5):3109-17
19648272
Hum Mol Genet. 2009 Oct 15;18(R2):R130-6
19808788
Arthritis Rheum. 2007 Nov;56(11):3564-74
17968936
Eur J Immunol. 2009 Sep;39(9):2317-24
19714572
J Immunol. 2006 Nov 15;177(10):6573-8
17082566
Immunity. 2006 Sep;25(3):417-28
16973389
Exp Cell Res. 2000 Nov 1;260(2):248-56
11035919
Nature. 2009 Mar 26;458(7237):514-8
19158675
Nat Genet. 2000 Jun;25(2):177-81
10835632
Cell Immunol. 2004 May;229(1):31-40
15331326
Rheumatology (Oxford). 2005 Sep;44(9):1101-7
15928001
Nature. 1995 Apr 6;374(6522):546-9
7700380
Blood. 2009 Jan 1;113(1):214-23
18824594
Nat Rev Rheumatol. 2010 Jan;6(1):21-9
19949432
Immunity. 1996 Oct;5(4):303-10
8885863
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10592-7
12947040
Arthritis Rheum. 2006 Mar;54(3):951-62
16508978
Arthritis Res Ther. 2008;10(5):218
18947369
Nature. 2009 Mar 26;458(7237):509-13
19158676
Nat Biotechnol. 2006 May;24(5):559-65
16648842
Immunol Res. 2009;43(1-3):98-108
18810334
J Exp Med. 2005 Mar 7;201(5):703-11
15738055
Exp Cell Res. 2009 Mar 10;315(5):760-8
19146850
J Immunol. 1999 Dec 1;163(11):6306-13
10570325
J Immunol. 2007 Jun 1;178(11):6876-85
17513736
J Immunol. 2010 Feb 15;184(4):1840-8
20089701
Immunol Rev. 2009 Nov;232(1):34-41
19909354
Blood. 2003 Sep 15;102(6):2243-50
12775567
J Immunol. 2009 Apr 1;182(7):4116-26
19299709
Nat Immunol. 2007 May;8(5):487-96
17417641
Cell Death Differ. 2008 Jan;15(1):183-91
17932498
Arthritis Rheum. 2005 May;52(5):1491-503
15880830
Curr Opin Immunol. 2006 Jun;18(3):286-91
16616474
Curr Opin Immunol. 2009 Jun;21(3):339-45
19493664
J Exp Med. 2004 Jun 21;199(12):1631-40
15197227
Blood. 2005 Sep 15;106(6):2200-5
15933051
Clin Chem. 2002 Aug;48(8):1212-7
12142376
PLoS One. 2009 Jun 02;4(6):e5776
19488401
Arthritis Rheum. 2006 Feb;54(2):408-20
16447217
Curr Dir Autoimmun. 2006;9:120-42
16394658
Mol Immunol. 2008 Apr;45(7):2038-44
18031817
Leukemia. 2006 Sep;20(9):1487-95
16791265